Balyasny Asset Management L.P. Buys 59,334 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Balyasny Asset Management L.P. grew its holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 277.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 80,743 shares of the company's stock after acquiring an additional 59,334 shares during the period. Balyasny Asset Management L.P. owned 0.14% of Ginkgo Bioworks worth $793,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of DNA. Bank of America Corp DE raised its position in shares of Ginkgo Bioworks by 780.6% in the fourth quarter. Bank of America Corp DE now owns 3,764,455 shares of the company's stock valued at $36,967,000 after purchasing an additional 3,336,964 shares during the period. Forbes J M & Co. LLP lifted its position in shares of Ginkgo Bioworks by 461.4% during the 4th quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company's stock worth $6,891,000 after purchasing an additional 576,732 shares during the last quarter. Erste Asset Management GmbH grew its holdings in Ginkgo Bioworks by 47.9% in the 4th quarter. Erste Asset Management GmbH now owns 739,332 shares of the company's stock valued at $6,979,000 after buying an additional 239,332 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new position in Ginkgo Bioworks in the 4th quarter worth approximately $1,796,000. Finally, BNP Paribas Financial Markets boosted its holdings in Ginkgo Bioworks by 80.6% in the 4th quarter. BNP Paribas Financial Markets now owns 285,111 shares of the company's stock valued at $2,800,000 after purchasing an additional 127,249 shares during the period. Institutional investors and hedge funds own 78.63% of the company's stock.

Ginkgo Bioworks Stock Down 1.0%

Ginkgo Bioworks stock traded down $0.08 during trading hours on Monday, hitting $7.85. The stock had a trading volume of 427,826 shares, compared to its average volume of 1,532,706. The company has a market cap of $455.57 million, a PE ratio of -0.60 and a beta of 1.29. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $5.00 and a fifty-two week high of $33.20. The company has a 50-day moving average of $7.17 and a two-hundred day moving average of $9.08.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.35). The company had revenue of $48.32 million during the quarter, compared to analyst estimates of $38.70 million. Ginkgo Bioworks had a negative net margin of 298.78% and a negative return on equity of 58.54%. As a group, analysts forecast that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current fiscal year.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.